Imatinib-associated hyperpigmentation of the palate in post-HSCT patient

Resende, Renata Gonçalves; Teixeira, Raissa Gabriela Lopes; Vasconcelos, Fabiana de Oliveira; Silva, Maria Elisa de Souza; Abreu, Mauro Henrique Guimarães; Gomez, Ricardo Santiago

doi:10.1016/j.jcms.2011.07.010

Cited by 24 publications

(37 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In one study of 118 patients with CML on imatinib, 41% of cases exhibited hypopigmentation of the skin, and only 4% of the cases showed hyperpigmentation [4]. There are other case reports showing the association between imatinib therapy and pigmentation of the hard palatal mucosa [5][6][7], nails [8], and skin [5]. Of the 8 total case reports of well-documented imatinib-associated pigmentation, all involved the mucosa of the hard palate.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Mucosal Pigmentation Caused by Imatinib: Report of Three Cases

Malik²,

Blaeser³

et al. 2011

Head and Neck Pathol

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

“…In five recently published articles, patients on imatinib were noted to develop cutaneous pigmentation [4,5], diffuse hyperpigmentation on the hard palate mucosa [5][6][7] or melanonychia [8].…”

Section: Introductionmentioning

confidence: 99%

Mucosal Pigmentation Caused by Imatinib: Report of Three Cases

Malik²,

Blaeser³

et al. 2011

Head and Neck Pathol

View full text Add to dashboard Cite

show abstract

“…Le premier cas de pigmentation buccale d'origine médicamenteuse a été rapporté par Lippard en 1945 chez un patient sous quinacrine [7]. Depuis, d'autres traitements ont été incriminés, les principaux étant la minocycline [6], la clofazimine, les anti-malaria [8], la quinidine, certains oestrogènes et contraceptifs oraux [9,10]. Des cas de pigmentations orales sous chimiothérapies anticancéreuses telles que les alkylants (busulfan et cyclophosphamide), la doxorubicine, le 5-fluorouracil ont aussi été rapportés [11].…”

Section: Discussionunclassified

“…Les principaux effets indési-rables sont des troubles digestifs, des oedèmes, des troubles hématopoïétiques à type de neutropénie et de thrombopénie. Au niveau cutané, l'hypopigmentation/dépigmentation est la complication la plus rapportée [9]. Paradoxalement, des hyperpigmentations existent [5,14].…”

Section: Discussionunclassified

See 1 more Smart Citation

Pigmentation palatine associée à un traitement par imatinib

Campana¹,

Ordioni²

2014

Med Buccale Chir Buccale

View full text Add to dashboard Cite

Association of oral mucosa hyperpigmentation with imatinib mesylate use: a cross-sectional study and a systematic literature review

et al. 2019

View full text Add to dashboard Cite

Objectives To assess the association between oral mucosa hyperpigmentation in patients with leukemia and imatinib mesylate use. Additionally, we compared our data to those obtained from a systematic review. Materials and methods A cross-sectional study was conducted with 74 patients undergoing treatment with imatinib mesylate. Sociodemographic characteristics, oral mucosa alterations, and medical history were evaluated. Oral hyperpigmentation was scored. The use of imatinib mesylate and hydroxyurea was evaluated. Association between oral hyperpigmentation and imatinib mesylate was assessed. A systematic review was also conducted to retrieve case reports or case series of patients with oral hyperpigmentation associated with imatinib mesylate. Results Among the 74 participants, 41 were male (55.4%) and 33 were female (44.6%). Participants' mean age was 49.3 years. Sixty-six (89.2%) patients developed hyperpigmented lesions in the hard palate mucosa. In multivariate analysis, patients who had used imatinib mesylate for > 72 months had a hyperpigmentation score 1.62 times higher than those who had used this medication during a shorter period. Patients who had used hydroxyurea for > 30 days had a hyperpigmentation score 1.43 times higher than those who had used this medication during a shorter period. The systematic review retrieved 20 clinical cases of patients undergoing imatinib mesylate treatment and exhibiting oral hyperpigmentation. Conclusions The development of oral hyperpigmentation is associated with imatinib mesylate use. Hydroxyurea seems to increment such an association. Clinical relevance To assist providers in the differential diagnosis of hyperpigmented lesions associated with imatinib mesylate, as well as in the clinical management of such lesions.

show abstract

Imatinib-associated hyperpigmentation of the palate in post-HSCT patient

Cited by 24 publications

References 28 publications

Mucosal Pigmentation Caused by Imatinib: Report of Three Cases

Mucosal Pigmentation Caused by Imatinib: Report of Three Cases

Pigmentation palatine associée à un traitement par imatinib

Association of oral mucosa hyperpigmentation with imatinib mesylate use: a cross-sectional study and a systematic literature review

Contact Info

Product

Resources

About